SCHEMBL5361085

SCHEMBL5361085

CNS(=O)(=O)c1csc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA3 P07451 2/20 0.48
CA4 P22748 2/20 0.48
CA6 P23280 2/20 0.48
CA5A P35218 2/20 0.48
CA7 P43166 2/20 0.48
CA9 Q16790 2/20 0.48
CA13 Q8N1Q1 2/20 0.48
CA14 Q9ULX7 2/20 0.48
CA5B Q9Y2D0 2/20 0.48
VCAM1 P19320 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
GAA P10253 2/20 0.41
LMNA P02545 3/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
HTT P42858 1/20 0.38
ALDH1A1 P00352 2/20 0.37
PTBP1 P26599 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9140997 0.76 DAO (0.41) CA2LMNAALDH1A1DAOMEN1
SCHEMBL31600989 0.74 ALDH1A1 (0.35) SMN1; SMN2LMNAHTTALDH1A1MEN1
SCHEMBL4875871 0.74 ALDH1A1 (0.42) ALDH1A1DAO
SCHEMBL5355039 0.72 DAO (0.43) CA2SMN1; SMN2LMNAALDH1A1DAO
SCHEMBL4106504 0.72 CA2 (0.45) CA12CA1CA2CA3CA4
SCHEMBL16002832 0.70 CA12 (0.61) CA12CA1CA2CA3CA4
SCHEMBL11478449 0.69 KMT2A (0.48) GAALMNAL3MBTL1HTTALDH1A1
SCHEMBL24425778 0.68 S100A9 (0.35) DAO
Hydrochloric Acid SCHEMBL31601091 0.68 DAO (0.35) CA12CA1CA2CA3CA4
SCHEMBL2371349 0.68 LMNA (0.61) CA12CA1CA2CA3CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227959-A1 Heterocyclic compound having oxime group STAT6, HRH4, HRH2 CA12 557/4885CA1 482/4885CA2 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.